Allianz Asset Management GmbH lowered its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,791 shares of the specialty pharmaceutical company’s stock after selling 418 shares during the period. Allianz Asset Management GmbH owned 0.18% of Jazz Pharmaceuticals worth $15,910,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Epoch Investment Partners Inc. increased its stake in shares of Jazz Pharmaceuticals by 18.3% during the 3rd quarter. Epoch Investment Partners Inc. now owns 79,971 shares of the specialty pharmaceutical company’s stock worth $11,696,000 after purchasing an additional 12,385 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in shares of Jazz Pharmaceuticals by 8.7% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,438,481 shares of the specialty pharmaceutical company’s stock worth $210,378,000 after purchasing an additional 115,217 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 7.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 247,170 shares of the specialty pharmaceutical company’s stock worth $36,151,000 after purchasing an additional 17,272 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 6.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 197,094 shares of the specialty pharmaceutical company’s stock worth $28,825,000 after purchasing an additional 11,428 shares during the last quarter. Finally, WINTON GROUP Ltd increased its stake in shares of Jazz Pharmaceuticals by 34.5% during the 3rd quarter. WINTON GROUP Ltd now owns 3,745 shares of the specialty pharmaceutical company’s stock worth $548,000 after purchasing an additional 961 shares during the last quarter. Institutional investors own 91.30% of the company’s stock.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $140.63 on Thursday. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals PLC has a fifty-two week low of $101.44 and a fifty-two week high of $163.75. The company has a market cap of $8,393.07, a price-to-earnings ratio of 17.57, a price-to-earnings-growth ratio of 0.90 and a beta of 0.98.

In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 352 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $133.19, for a total value of $46,882.88. Following the completion of the transaction, the director now directly owns 1,365 shares of the company’s stock, valued at approximately $181,804.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,552 shares of company stock valued at $2,549,643. Insiders own 4.30% of the company’s stock.

Several brokerages have recently issued reports on JAZZ. UBS decreased their price target on shares of Jazz Pharmaceuticals from $172.00 to $168.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. Morgan Stanley initiated coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 5th. They set an “equal weight” rating and a $155.00 price target for the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Sunday, December 3rd. B. Riley reaffirmed a “buy” rating and issued a $206.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, December 5th. Finally, Cowen set a $190.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 21st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $181.28.

WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Shares Sold by Allianz Asset Management GmbH” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-shares-sold-by-allianz-asset-management-gmbh/1762710.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.